Soligenix announces topline results from its phase 3 clinical trial of sgx942 for the treatment of oral mucositis in head and neck cancer patients

Princeton, n.j., dec. 22, 2020 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary...
SNGX Ratings Summary
SNGX Quant Ranking